...
首页> 外文期刊>The Urologic clinics of North America >Prostate cancer: radical prostatectomy.
【24h】

Prostate cancer: radical prostatectomy.

机译:前列腺癌:前列腺癌根治术。

获取原文
获取原文并翻译 | 示例
           

摘要

Today, more men than ever before are being followed after radical prostatectomy. Prognosis and follow-up should be based on the pathologic specimen. Measurable prostate-specific antigen (PSA) after surgery defines failure, with time to detectable PSA and rate of PSA rise being useful prognostic factors. The natural history of untreated biochemical failure is protracted, a fact to be considered in discussions of adjuvant treatment. Early in disease recurrence, imaging studies to locate residual disease rarely are useful clinically. Both adjuvant and salvage radiation to the prostate bed have benefits and risks, but neither is superior in overall prostate cancer survival. The timing of hormone therapy remains largely empiric. The promise of effective cytotoxic chemotherapy still is greater than its actual benefits, although novel cytostatic agents are being developed. The future management of this disease will improve with better molecular definition of risk and therapeutic response.
机译:如今,前列腺癌根治术后的男性人数比以往任何时候都要多。预后和随访应基于病理标本。手术后可测量的前列腺特异性抗原(PSA)定义了失败,可检测PSA的时间和PSA升高的速度是有用的预后因素。未经治疗的生化衰竭的自然病程很长,在讨论辅助治疗时应考虑这一事实。在疾病复发的早期,很少有影像学研究来定位残留疾病在临床上是有用的。辅助放射线和挽救性放射线对前列腺床都有益处和风险,但在总体前列腺癌生存率方面均不优越。激素治疗的时机在很大程度上仍然是经验性的。尽管正在开发新型的细胞抑制药物,有效的细胞毒性化学疗法的前景仍然大于其实际收益。随着对风险和治疗反应的更好分子定义,该疾病的未来管理将得到改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号